MX2023013912A - Metodos para inhibir ras. - Google Patents
Metodos para inhibir ras.Info
- Publication number
- MX2023013912A MX2023013912A MX2023013912A MX2023013912A MX2023013912A MX 2023013912 A MX2023013912 A MX 2023013912A MX 2023013912 A MX2023013912 A MX 2023013912A MX 2023013912 A MX2023013912 A MX 2023013912A MX 2023013912 A MX2023013912 A MX 2023013912A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- inhibiting ras
- inhibiting
- ras
- disclosure
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163192837P | 2021-05-25 | 2021-05-25 | |
| PCT/US2022/030823 WO2022251292A1 (en) | 2021-05-25 | 2022-05-25 | Methods for inhibiting ras |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023013912A true MX2023013912A (es) | 2024-02-12 |
Family
ID=82115695
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023013912A MX2023013912A (es) | 2021-05-25 | 2022-05-25 | Metodos para inhibir ras. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240277796A1 (https=) |
| EP (1) | EP4346898A1 (https=) |
| JP (1) | JP2024521774A (https=) |
| KR (1) | KR20240026526A (https=) |
| CN (2) | CN118557730A (https=) |
| AU (1) | AU2022281343A1 (https=) |
| CA (1) | CA3219533A1 (https=) |
| IL (1) | IL308771A (https=) |
| MX (1) | MX2023013912A (https=) |
| TW (1) | TW202313631A (https=) |
| WO (1) | WO2022251292A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2022005359A (es) | 2019-11-04 | 2022-06-02 | Revolution Medicines Inc | Inhibidores de ras. |
| MX2023003060A (es) | 2020-09-15 | 2023-04-05 | Revolution Medicines Inc | Derivados indolicos como inhibidores de ras en el tratamiento del cancer. |
| AU2022268962A1 (en) | 2021-05-05 | 2023-12-14 | Revolution Medicines, Inc. | Ras inhibitors for the treatment of cancer |
| AR127308A1 (es) * | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| CN118922423A (zh) * | 2022-01-10 | 2024-11-08 | 锐新医药公司 | Ras抑制剂 |
| CN119301132A (zh) * | 2022-06-01 | 2025-01-10 | 豪夫迈·罗氏有限公司 | 用于治疗癌症的卤代吲哚大环化合物 |
| CN119522225A (zh) | 2022-09-29 | 2025-02-25 | 广州嘉越医药科技有限公司 | 大环衍生物及其应用 |
| CR20250329A (es) | 2023-02-14 | 2025-09-12 | Hoffmann La Roche | Compuestos tricíclicos para el tratamiento del cáncer |
| EP4687905A1 (en) * | 2023-03-30 | 2026-02-11 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| TW202446387A (zh) * | 2023-04-06 | 2024-12-01 | 瑞士商赫孚孟拉羅股份公司 | 用於治療癌症之三環化合物 |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| WO2025019318A2 (en) * | 2023-07-14 | 2025-01-23 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2025162395A1 (zh) * | 2024-02-01 | 2025-08-07 | 山东先声生物制药有限公司 | 吲哚衍生物作为ras抑制剂及其应用 |
| CN119431325A (zh) * | 2024-10-31 | 2025-02-14 | 诚达药业股份有限公司 | 一种3-（1h-吡唑-1-基）氮杂环丁烷类化合物及其合成方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210116479A (ko) | 2018-12-21 | 2021-09-27 | 레볼루션 메디슨즈, 인크. | 공동 결합에 참여하는 화합물 및 그의 용도 |
| DE102019122206B4 (de) | 2019-08-19 | 2021-07-08 | Webasto SE | Dachmodul zur Bildung eines Fahrzeugdachs mit Umfeldsensor |
| MX2022005359A (es) | 2019-11-04 | 2022-06-02 | Revolution Medicines Inc | Inhibidores de ras. |
| CN120699039A (zh) | 2019-11-04 | 2025-09-26 | 锐新医药公司 | Ras抑制剂 |
| WO2021091956A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
| MX2023003060A (es) | 2020-09-15 | 2023-04-05 | Revolution Medicines Inc | Derivados indolicos como inhibidores de ras en el tratamiento del cancer. |
-
2022
- 2022-05-25 MX MX2023013912A patent/MX2023013912A/es unknown
- 2022-05-25 CN CN202410561373.XA patent/CN118557730A/zh active Pending
- 2022-05-25 EP EP22731928.2A patent/EP4346898A1/en active Pending
- 2022-05-25 CA CA3219533A patent/CA3219533A1/en active Pending
- 2022-05-25 JP JP2023572737A patent/JP2024521774A/ja active Pending
- 2022-05-25 KR KR1020237044138A patent/KR20240026526A/ko active Pending
- 2022-05-25 AU AU2022281343A patent/AU2022281343A1/en active Pending
- 2022-05-25 IL IL308771A patent/IL308771A/en unknown
- 2022-05-25 TW TW111119516A patent/TW202313631A/zh unknown
- 2022-05-25 CN CN202280050079.1A patent/CN117715658A/zh active Pending
- 2022-05-25 WO PCT/US2022/030823 patent/WO2022251292A1/en not_active Ceased
-
2023
- 2023-11-22 US US18/518,027 patent/US20240277796A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN117715658A (zh) | 2024-03-15 |
| TW202313631A (zh) | 2023-04-01 |
| JP2024521774A (ja) | 2024-06-04 |
| US20240277796A1 (en) | 2024-08-22 |
| IL308771A (en) | 2024-01-01 |
| CA3219533A1 (en) | 2022-12-01 |
| CN118557730A (zh) | 2024-08-30 |
| WO2022251292A1 (en) | 2022-12-01 |
| EP4346898A1 (en) | 2024-04-10 |
| KR20240026526A (ko) | 2024-02-28 |
| AU2022281343A1 (en) | 2023-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023013912A (es) | Metodos para inhibir ras. | |
| IL308195A (en) | RAS inhibitors for cancer treatment | |
| ZA202003176B (en) | Compounds useful as kinase inhibitors | |
| PH12021553000A1 (en) | Multispecific proteins | |
| PH12018500587A1 (en) | Pyrazolopyrimidine derivatives as btk inhibitors for the treatment of cancer | |
| PH12022551013A1 (en) | Pyridazinones as parp7 inhibitors | |
| MX2020012797A (es) | Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso. | |
| MX2019001471A (es) | Anticuerpos anti-siglec-7 para el tratamiento del cancer. | |
| MX2024003713A (es) | Usos de moleculas de union al antigeno multiespecificas dirigidas al ligando tipo delta 3 (dll3). | |
| EP4302835A3 (en) | Methods of treating ovarian cancer | |
| MX392368B (es) | Composiciones y metodos para el tratamiento del cancer | |
| EA201791736A1 (ru) | Комбинированная терапия для лечения рака | |
| PH12020552214A1 (en) | Ectonucleotidase inhibitors and methods of use thereof | |
| AU2018301696A8 (en) | Heterocyclic inhibitors of ATR kinase | |
| MX2020006297A (es) | Variantes de cd19. | |
| MX2022007955A (es) | Regimenes de dosificacion de erdafitinib. | |
| WO2020055643A3 (en) | Compounds, compositions and methods for treating or preventing her-driven cancers | |
| MX2020012291A (es) | Compuestos para el tratamiento de cancer de mama triple negativo y cancer de ovario. | |
| MX2021008834A (es) | Metodos de tratamiento del cancer de mama con tucatinib. | |
| MX2020012990A (es) | Formulaciones de tegavivint y compuestos relacionados. | |
| MX2021009863A (es) | Una molecula dbait en combinacion con inhibidor de quinasa para el tratamiento del cancer. | |
| PH12018501943A1 (en) | Pharmaceutical compositions for the treatment of cancer | |
| WO2020033019A3 (en) | Novel mct4 inhibitors and uses thereof | |
| ZA202106807B (en) | Antibodies having specificity for btn2 and uses thereof | |
| WO2021102359A3 (en) | Taspase1 inhibitors and uses thereof |